ArchiMed has acquired a majority stake in Switzerland-based Stragen Pharma, a company that produces generic drugs for complex and life-threatening illnesses.
ArchiMed has acquired a majority stake in Switzerland-based Stragen Pharma, a company that produces generic drugs for complex and life-threatening illnesses.